Profile change history
A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Petrelintide identity.
Before and after
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Collection chronology
Showing the latest 6 additions by PeptideScanner publication date; the complete connected record set remains available in Latest Research. Most recent addition: August 14, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT07589686 at 2026-08-13T05:52:27.014Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT07682818 at 2026-08-10T18:10:03.938Z. Its registry update date was 2026-07-06, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained PubMed bibliographic metadata for PMID 42017294 at 2026-08-10T18:13:48.775Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-04-22. PeptideScanner associated this retained record with the identity slug petrelintide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.
ClinicalTrials.gov lists a Petrelintide study that is not yet recruiting sponsored by Hoffmann-La Roche.